SARS-CoV-2 - Telmisartan - Therapeutic Candidates

SARS-CoV-2 - Telmisartan - Therapeutic Candidates


Telmisartan is an angiotensin II inhibitor. It blocks the action of angiotensin II through its antagonistic function on the receptors for this substance naturally present in the body, which causes contraction of the arteries and increases arterial pressure. Telmisartan is therefore an antihypertensive drug used in the treatment of high blood pressure and chronic renal failure. Telmisartan has several advantages: its half-life is 24 hours (longer than other angiotensin II receptor antagonists) and it does not alter the metabolism of bradykinin (unlike ACE inhibitors), which avoids associated side effects such as coughing.
Studies have shown that during SARS-Cov-6 infection, alveolar cell ACE2 protein is targeted. The loss of the enzymatic action of ACE2 leads to an increase in the concentration of angiotensin II. This would be the starting point for the cytokine storm described in the most affected Covid-19 patients. For this reason, clinical studies have been initiated to test the effect of telmisartan on the development of acute respiratory distress syndrome (ARDS) in Covid-19 patients.

Search result : 163 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 36
  • all species 1
  • Biochemicals 126
  • Inhibitor/Antagonist/Agonist 27
  • Buffers and reagents 9
  • Primary antibody 1
  • rabbit 1
  • ELISA 1
  • WB 1
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
orb1308143-1g
 1g 
orb1902884-500mg
 500mg 
orb1226257-25mg
 25mg 
T1570-1g
 1g 
T1570-25mg
 25mg 
T1570-50mg
 50mg 
T1570-500mg
 500mg 
T1570-1mL
 1mL 
T1570-100mg
 100mg 
T1570-200mg
 200mg 
HY-13955-500mg
 500mg 
HY-13955-50mg
 50mg 
M3289-50mg
 50mg 
256896-50mg
 50mg 
M3289-100mg
 100mg 
289877-1g
 1g 
256896-10mg
 10mg 
289877-250mg
 250mg